| ||||||||||||||||||||||||
|
Be the First to know sign up for our TWITTER
MedWatch |
The FDA Safety Information and Adverse Event Reporting Program Medwatch Alert for Lung Transplant Recipients FDA and Roche notified healthcare professionals of the findings of an active comparator study of Valcyte and ganciclovir in heart, liver, kidney, and kidney-pancreas transplant patients at high risk for CMV disease. Based on those findings: (1) Valcyte is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk, (2) Valcyte is not indicated for use in liver transplant patients, and (3) The safety and efficacy of Valcyte for the prevention of CMV disease in other solid organ transplant patients, such as lung transplant patients, have not been established. Read the 2003 MedWatch safety summary, including a link to the "Dear Healthcare Professional" letter, at: http://www.fda.gov/medwatch/SAFETY/2003/safety03.htm#valcyte
Return Home | Return to Education Resources | Return to Informational Resources Telephone: 540-948-6777 or 1-866-FOR-A1AA (1-866-367-2122) Fax # 540-948-6763 Copyright © 2009 Alpha-1 Advocacy Alliance, All Rights Reserved Home | Disclaimer | Privacy Policy | |||||||||||||||||||||||